The biotech industry has grown significantly and is well-positioned to remain buoyed due to significant strides in drug development, government support, and technological advancements.
Given this backdrop, fundamentally robust biotech stocks Gilead Sciences, Inc. (GILD), Equillium, Inc. (EQ), Incyte Corporation (INCY), and Jazz Pharmaceuticals plc (JAZZ) could be solid buys now. These stocks are rated A (Strong Buy) in our proprietary POWR Ratings system.
